NEW YORK, Nov. 15, 2016 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Ligand Pharmaceuticals Incorporated ("Ligand" or the "Company") (NASDAQ: LGND), concerning whether the board has breached its fiduciary duties to shareholders.
On November 14, 2016, the Company disclosed that it would be forced to restate its previously issued financial statements for the third and fourth quarters of 2015, and the first and second quarters of 2016 due to accounting errors.
Our investigation concerns whether the Company board of directors has breached its fiduciary duties to shareholders, grossly mismanaged the Company, and/or committed abuses of control in connection with the foregoing.
If you own Ligand shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:
Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm.
Attorney Advertising. The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.